Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Corporation Stock Sank Last Month

By George Budwell – Apr 9, 2018 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MannKind may be on its last leg.

What happened

Shares of MannKind Corporation (NASDAQ: MNKD), a small-cap biotech commercializing the inhaled insulin product Afrezza, shed 22.2% of their value in March, according to S&P Global Market Intelligence . What sent MannKind's shares spiraling downward?

MannKind's stock moved lower in response to the company's clear need to raise capital. Complicating matters more, the biotech's shares were further hampered by the ongoing risk avoidance behavior among investors resulting from President Trump's trade war with China. 

An hourglass close to running out of sand.

Image source: Getty Images.

So what

Predictably, MannKind did turn to the markets to raise capital last week to the tune of $28 million. In response, the drugmaker's shares fell by another 24.8% last Friday. With the markets in revolt over Trump's controversial trade policies, MannKind's stock may have trouble finding a bottom anytime soon. 

Now what

Can MannKind avoid further dilutive capital raises and a possible date with bankruptcy court? Even though Afrezza's sales are picking up to some degree, the long and short of it is that the drug's commercial launch would need to kick into overdrive to save MannKind at this point.

After all, the biotech only has about two quarters of cash remaining after this latest financing, implying that it will tap the markets yet again within the next month or so. That's not a sound plan for share-price appreciation, quite frankly. 

As a more immediate concern, MannKind's shares have now fallen below the $2 mark and they seem to be headed even lower in the near term. Consequently, the company may soon be facing another delisting notification from the Nasdaq stock exchange. MannKind therefore seems to be quickly running out of time to turn its business around.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.